PharmaTalkRadio

Adapted from the 2016 Chief Medical Officer Summit keynote address, Dr Akshay Vaishnaw, who serves as EVP of R&D and CMO at Alnylam Pharmaceuticals, tackles the challenges and opportunities in pursuing a new therapeutic modality from its inception.

The Chief Medical Officer Summit is designed for CMOs and R&D Leadership from small to mid-size life science companies. The 6th Annual CMO Summit will be held May 7-8, 2018, in Boston.

At the 2017 Partners Europe event in London, Nicholas Brooke, Chief Executive, Patient Focused Medicines Development (PFMD) and Jan Geissler, Director, European Patients’ Academy on Therapeutic Innovation (EUPATI) call on industry to partner with patients in the development and lifecycle of medicines.

The Patients as Partners Europe program seeks to understand and incorporate the patient's voice in designing clinical trials and developing a clinical endpoint, as well as vastly improve the patient's entire experience in a clinical trial. The 2nd annual Patients as Partners EU event will be held January 23-24, 2018 at Radisson Blu Portman Hotel, London, UK.

Dr Axel Hoos, GSK, leads a panel discussion on Trends and Collaborations in the Immuno-Oncology Space, featuring Dr Ramy Ibrahim, VP and Head of R&D, Parker Institute for Cancer Immunotherapy; Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs, Cancer Research Institute; Dr Daniel Chen, VP, Global Head of Cancer Immunotherapy Development, Genentech; and David Wholley, MPhil, Director, Research Partnerships Division, Foundation for the National Institutes of Health.

The 4th Annual IO360° conference will take place February 7-9, 2018 in New York City.

At the inaugural Patients as Partners Europe event, Duncan Arbour from inVentiv Health explores the ‘how’ and ‘when’ for involving patients within clinical and commercial to enhance the development and delivery of innovative therapies. 

The patient voice as a strategic driver is being included much earlier in the development process than ever before. In this session, pharmaceutical, biotech and device companies will gain insight into the value of smarter patient integration. Key focus areas include:

• The critical shift from drug-centric to patient-relevant

• Pivotal patient touch points throughout clinical development and launch planning that will maximize both clinical and commercial outcomes

• Positive impact of integration on efficiency and commercialization

The Patients as Partners Europe program seeks to understand and incorporate the patient's voice in designing clinical trials and developing a clinical endpoint, as well as vastly improve the patient's entire experience in a clinical trial. The 2nd annual Patients as Partners EU event will be held January 23-24, 2018 at Radisson Blu Portman Hotel, London, UK.

Alastair Kent, Director of the Genetic Alliance UK, talks about how patients can and are influencing policy within the EU. 

The Patients as Partners Europe program seeks to understand and incorporate the patient's voice in designing clinical trials and developing a clinical endpoint, as well as vastly improve the patient's entire experience in a clinical trial. The 2nd annual Patients as Partners EU event will be held January 23-24, 2018 at Radisson Blu Portman Hotel, London, UK.

Originally presented during the business aspects plenary session at Immuno-Oncology 360° 2017, Dr Axel Hoos of GSK discusses business models for complex science. 

Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City. Dr Hoos returns as lead advisor, as well as moderating a talk called, "Investor Roundtable: The Role of IO within Large Pharma - Where Does it Stand?" with panelists from Citi, Atlas Venture, New Enterprise Associates, and SR One Ltd.

Chief Medical Officer at nanoString Technologies, Dr Alessandra Cesano, brings to light the increasingly critical role of predictive biomarkers in cancer immunotherapy, originally presented during the translational science and new technologies session from 2017’s Immuno-Oncology 360° conference.

Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City.

About Dr Cesano:

Alessandra Cesano, MD, PhD has served as CMO at nanoString since July 2015. Prior to joining the company, Dr Cesano was Chief Medical Officer at Cleave Biosciences, Inc. From 2008 to 2014, she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc, where she built and led the R&D groups, while providing the overall clinical vision for the organization. In addition, Dr Cesano has held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals. Dr Cesano spent 12 years researching tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center at the University of Pennsylvania. She also holds membership in several professional and scientific societies, and has been an author on over 100 research publications.

Originally recorded during a panel session at the 2017's Immuno-Oncology 360°, Mark Simon of Torreya Partners moderates the conversation around issues, controversies, and other important business aspects of IO. He's joined by IO360° lead advisor and SVP at GSK, Dr Axel Hoos, Dr Robert Ang of Neon Therapeutics, Dr Jeffrey Bockman from Defined Health, Dr Jeffrey Legos from Novartis Pharmaceuticals, and Dr Chandra Ramanathan at Bayer Healthcare.

Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City.

Originally recorded during the 3rd annual Immuno-Oncology 360° in February 2017, this panel discussion addresses clinical challenges within immuno-oncology. One of the IO360° lead advisors, Dr James Gulley of the National Cancer Institute, moderates the session between Merck’s Dr Roy Baynes, nanoString Technologies’ Dr Alessandra Cesano, MD Anderson’s Dr Patrick Hwu, and inVentiv Health’s Robert Millham.

Dr Hwu and Dr Baynes are also speaking on the 2nd annual Rational Combinations 360° program in June 2017, which is an exciting meeting dedicated to combination therapy in IO.

Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City.

Originally recorded at the inaugural Patients as Partners Europe event, held in London in February 2017. Patient, industry, and regulatory perspectives are provided by Alastair Kent of Genetic Alliance UK, Dr Anton Hoos of Amgen Europe, and Isabelle Moulon of the EMD as they discuss on innovative ways of to include patient involvement in medicines development.

The Patients as Partners Europe program seeks to understand and incorporate the patient's voice in designing clinical trials and developing a clinical endpoint, as well as vastly improve the patient's entire experience in a clinical trial. The 2nd annual Patients as Partners EU event will be held January 23-24, 2018 at Radisson Blu Portman Hotel, London, UK.